The DOI matches its Crossref record.
High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
Open accessAbstract
BACKGROUND: 131 I‐Metaiodobenzylguanidine (131 I‐MIBG) can be used systemically to treat malignant pheochromocytoma. To improve outcome, the authors used higher levels of activity of 131 I‐MIBG than previously reported. The authors reported the response rates and toxicity levels in patients with malignant pheochromocytoma or paraganglioma who were treated with high‐dose 131 I‐MIBG. METHODS: Following debulking surgery and stem cell harvest, 12 patients with malignant pheochromocytoma or paraganglioma were treated with 131 I‐MIBG. Five had received previous external beam radiation and/or chemotherapy. The median single treatment dose was 800 mCi (37 gigabecquerels; range, 386–866 mCi) or 11.5 mCi/kg (range, 5.6–18.3 mCi/kg). The median cumulative dose was 1015 mCi (range, 386–1690 mCi). RESULTS: Three patients had a complete response, two of whom had soft tissue and skeletal metastases. Their median follow‐up was 45 months (range, 23–101 months). Seven patients had a partial response (PR), with a median follow‐up 43 months (range, 6–47 months). Two patients without a response died with progressive disease (PD) and 2 patients with an initial PR died of PD at 13 and 11 months, respectively. Grade 3 thrombocytopenia occurred after 79% (15 of 19) of treatments had been administered. Grade 3 and 4 neutropenia followed 53% (10 of 19) and 19% (4 of 19) of treatments, respectively. One patient required stem cell infusion, and one developed primary ovarian failure. CONCLUSIONS: The single and cumulative doses of 131 I‐MIBG were approximately 2–3.5 times higher than those used at other centers. Unlike previous reports, two patients with both skeletal and soft tissue metastases had a complete response. Hematologic toxicity was significant but tolerable. High‐dose 131 I‐MIBG may lead to long‐term survival in patients with malignant pheochromocytoma. Cancer 2003;98:239–48. © 2003 American Cancer Society. DOI 10.1002/cncr.11518
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N.-K. V., Dahia, P. L., de Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., et al. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00829 · Cited by 338
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0074 · Cited by 314
Metadata
- Authors
- Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., & Fitzgerald, P. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-07-02
- Volume
- 98
- Issue
- 2
- Pages
- 239-248
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2010956382
- Cited by
- 158
- References
- 0
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. https://app.cochat.ai/papers/10.1002/cncr.11518
- The paper
- Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., & Fitzgerald, P. A. (2003). High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. https://doi.org/10.1002/cncr.11518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.